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http://dx.doi.org/10.1016/j.jacl.2015.1OBJECTIVE: To describe real-life patterns of statin use and cholesterol goal attainment in a
retrospective cohort of patients with high cardiovascular risk.
METHODS: Retrospective cohort study of 21,636 individuals, 18.34% women, mean age 63.30 years
(standard deviation 6.29). New statin users aged 35 to 74 years at high cardiovascular risk and with no
previous cardiovascular disease in primary care electronic medical records (2006–2011). Patterns of
statin use were based on statin type, potency, and 1-year statin switches.
OUTCOMES: Relative mean reductions over 1 year and probability of goal attainment (,3.3 mmol/L).
Natural patterns of statin use were identified using multiple correspondence analysis; general linear and
logistic models were used to estimate low-density lipoprotein cholesterol (LDL-C) reductions and goal
attainment probability.
RESULTS: Three patterns of statin use were defined: low (3.82% of the population), moderate
(71.94%), and high intensity (24.24%). After 1 year, potency decreased 42.74%, 64.16%, and 50.94%,
respectively, and 37.41%, 29.47%, and 30.16% of the population stopped taking statins in low, moderate,
and high patterns, respectively. Relative reductions in LDL-C: low intensity, 15.7% (95% confidence
interval [CI]:222.96 to 54.36); moderate intensity, 29.72% (95% CI: 29.12–30.32); and high intensity,
24.20% (95% CI: 28.08 to 40.32). There was a direct relationship between higher intensity patterns
and greater probability of goal attainment.Investigacio en Atencio Primaria
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Garcıa-Gil et al Statin use and goal attainment in a high-risk population 135CONCLUSIONS: Three real-life patterns of statin use were identified. Lipid management strategies in
primary care should focus on improving adherence to treatment. People starting at low potency should
switch to a moderate pattern; more intensive therapies should be considered in who require a larger
LDL-C reduction to reach therapeutic targets, patients with good treatment adherencewho do not achieve
the goal with a moderate pattern of therapy or patients at very high risk.
 2016 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Statin effectiveness in reducing low-density lipoprotein
cholesterol (LDL-C) levels is well known in high-risk
populations and secondary prevention.1,2 It is estimated that
1-mmol/L reduction in LDL-C may reduce 5-year incidence
of cardiovascular events and coronary revascularization by
one fifth,1 and a similar effect has been observed in a compa-
rison of intensive and less-intensive statin regimens.3,4 In
addition, a study by Cholesterol Treatment Trialists’
Collaboration showed that a 1-mmol/L reduction in LDL-C
safely reduces 5-year incidence of cardiovascular events
and coronary revascularization in low-risk populations by
10%, regardless of age, gender, and baseline LDL-C.5
The recommended management of patients with
dyslipidemia, including the patterns of statin use to achieve
recommended thresholds, differs substantially between the
European Society of Cardiology/European Atherosclerosis
Society6 and the American College of Cardiology/
American Heart Association.7 In both the cases, however,
recommended patterns of statin use are based on their
capacity to lower baseline LDL-C levels.
Despite these guidelines,6,7 observational studies show that
the recommended goals are not being achieved in primary
prevention populations, community settings,8–11 or secondary
prevention.12,13 These results may be partly related to the real-
life patterns of statin use.14–16 Patterns of statin use have been
studied in specific populations, such as diabetics, and in second-
ary prevention,12,13 but real-life studies in primary prevention
and other high-risk populations are scarce.17 Further description
of these patterns may help to improve the management of these
populations and attainment of the recommended goals.
The aim of the present study of primary care electronic
medical records was to describe real-life patterns of statin
use and cholesterol goal attainment in a retrospective
cohort of patients with high cardiovascular risk and no





The Information System for the Development of
Research in Primary Care (SIDIAP) is a clinical databaseof anonymized longitudinal patient records for nearly 6
million people (80% of the Catalan population and 10.2%
of the total population of Spain) registered in 274 primary
care practices having a total of 3414 general practitioners
(GPs).18 A subset of records from GPs who surpass
predefined data quality standards19 constitutes the
SIDIAPQ, which provides research-quality anonymized
data on approximately 2 million patients. The information
recorded includes demographic and lifestyle factors
relevant to primary care settings (body mass index [BMI],
smoking status, alcohol use, and so forth); clinical
diagnoses, outcomes, and events (coded according to the
International Classification of Diseases, 10th revision);
referrals and laboratory tests; and prescribed medications
actually dispensed by community pharmacies. The quality
of SIDIAP data has been previously documented, and the
database has been widely used to study the epidemiology
of a number of health outcomes.20–23
Study population and inclusion criteria
All new statin users aged 35 to 74 years, at high
cardiovascular risk and without previous history of
cardiovascular disease (symptomatic peripheral arterial
disease, coronary heart disease, stroke, or revascularization
procedures) as recorded in SIDIAPQ between July 2006 and
December 2010 were eligible for inclusion.
Coronary heart disease risk was calculated using the
Framingham function adapted and validated in the Spanish
population by the Registre Gironı del Cor study24 and the
systematic coronary risk evaluation function.25 High
cardiovascular risk was defined as Registre Gironı del Cor
10-year risk $ 10% or systematic coronary risk evaluation
$ 5%.
Study entry and follow-up
Study period was from July 2006 through December
2011, with enrollment from July 2006 to December 2010.
Patients were censored at the date of death, transfer from
SIDIAPQ, or the end of the study period (31December 2011).Statin exposure
To prevent survivor bias and covariate measurement
bias, a ‘‘new users design’’ was selected over ‘‘all statin
users’’. New users were defined as receiving statins for the
136 Journal of Clinical Lipidology, Vol 10, No 1, February 2016first time or after a hiatus of at least 6 months. The date of
this new statin prescription was considered the index date.
Statin exposure was calculated according to the
definition of 1-year adherence, or Medical Possession Ratio
(MPR): the number of days of statin supplied during 12
consecutive months, divided by 365 days.
Outcomes
Patterns of statin use were based on the following
variables:
- Statin type: simvastatin, pravastatin, lovastatin, fluvasta-
tin, rosuvastatin, or atorvastatin.
- Statin potency, classified by LDL-C reduction.26,27
 Low (,30% reduction): 20 to 40-mg fluvastatin, 10 to
20-mg lovastatin, 10-mg pravastatin, or 5-mg
simvastatin.
 Moderate (30%–40% reduction): 10 to 20-mg
atorvastatin, 80-mg fluvastatin, 40-mg lovastatin, 20
to 40–80-mg pravastatin, or 10 to 20-mg simvastatin.
 High (40%–50% reduction): 40-mg atorvastatin, 40 to
80-mg simvastatin, or 5-mg rosuvastatin.
 Very high (.50% reduction): 80-mg atorvastatin or
10 to 20–40-mg rosuvastatin.
- Statin switches: combination of any change in statin type
or potency change at 1 year after treatment initiation.
Accordingly, the following scenarios were defined:
 No statin change and no potency change
 No statin change and increased potency
 No statin change and decreased potency
 Statin change and no potency change
 Statin change and increased potency
 Statin change and decreased potency
 Stopped taking statin: no statin invoicing in the
6 months beyond the end of study follow-up.LDL cholesterol goal attainment
Attainment was assessed by relative mean reductions
during 1-year follow-up and the probability of goal
attainment (yes/no). Data are presented for the probability
of LDL-C goal attainment at values ,3.36 mmol/L and
,2.59 mmol/L. The study analyzed a goal of LDL-C
, 3.36 mmol/L in accordance with the local
guidelines that were in place during the study period
(2006–2011). The current recommended goal for control
of dyslipidemia in the high-risk primary prevention
populations with low incidence of cardiovascular events is
LDL-C , 2.59 mmol/L.28
Covariates
Anonymized baseline patient characteristics were
obtained from SIDIAPQ: age, gender, systolic blood
pressure and diastolic blood pressure, BMI, vascular
risk factors (obesity, diabetes mellitus, hypertension,
dyslipidemia, smoking, high-risk alcohol intake), and totalcholesterol, LDL-C, high-density lipoprotein cholesterol
(HDL-C), triglycerides, and glucose levels.
Statistical analysis
Categorical variables are presented as percentages and
continuous variables as mean (standard deviation [SD]) or
median [first–third quartiles], as appropriate. We used 10
multiple imputations by chained equations29 to replace base-
line and 1-year missing values for total cholesterol, LDL-C,
triglycerides, glucose, systolic blood pressure, diastolic
blood pressure, and BMI. The specific characteristics of
the study population (high-risk patients) made the missing-
at-random assumption plausible. In addition to incorporating
the missing-at-random assumption, we conducted a
sensitivity analysis, comparing case-complete results with
the multiple imputation process. Only individuals being
part of all imputations were included in the analysis.
Natural patterns of statin use based on statin type,
potency, and 1-year change were identified using multiple
correspondence analysis (MCA), which allows representa-
tion in N-multidimensional space of relationships between
a set of categorical variables that would otherwise be
difficult to observe in contingency tables30 and to show
groups of individuals with the same characteristics. From
the multidimensional space created, individuals were
classified in patterns according to proximity criteria by
means of the k-means algorithm, using 1000 different seeds
and 40 iterations.31
Relative mean reductions in LDL-C were calculated,
and logistic models were used to estimate the probability of
goal attainment by patterns of statin use identified by MCA.
Two analyses were performed: a first analysis including all
individuals regardless of adherence, which reflects real life,
and a second analysis including only individuals with high
adherence (MPR$ 70%), to test sensitivity. Logistic models
were further adjusted for gender, age, diabetes, hypertension,
smoking, and total-cholesterol and glucose levels.
Results
Between 2006 and 2010, 21,636 individuals fulfilled all
inclusion criteria. Only 159 participants were lost to follow-
up, all of them due to transfer out of the SIDIAPQ database.
The missing data for incomplete variables and a
comparison of complete-case data set and the completed
(imputed) data set are shown in Supplementary Tables S1–S7.
Baseline characteristics
Women constituted 18.34% of the sample. Mean age and
median cardiovascular risk were 63.30 (SD 6.29) and 11.75
[1st 9.76–3rd 14.90] years, respectively. Diabetes was
present in 56% of participants, hypertension in nearly
68%, smoking in 52%, and dyslipidemia in 71%. Total-
cholesterol and LDL-C goal attainment were achieved by
10.78% and 18.95% of participants, respectively (Table 1).










CV risk* 11.75 (9.76–14.90)
BMI* 29.92 (4.85)
SBP, mm Hg* 143.85 (16.93)
DBP, mm Hg* 81.97 (10.63)
Total-C, mmol/L* 6.48 (1.11)
Total-C , 5.17 mmol/L 10.78
1-y Total-C, mmol/L* 5.16 (1.11)
1-y Total-C , 5.17 mmol/L 54.48
HDL-C, mmol/L* 1.24 (0.31)
LDL-C, mmol/L* 4.20 (1.02)
LDL-C , 3.36 mmol/L 18.95
LDL-C , 2.59 mmol/L 5.06
1-y LDL-C, mmol/L* 3.06 (1.11)
1-y LDL-C , 3.36 mmol/L 63.72
1-y LDL-C , 2.59 mmol/L 34.68
Triglycerides, mmol/L* 1.82 (1.32–2.60)
Glucose, mmol/L* 7.46 (2.94)
BMI, body mass index; CV, cardiovascular; DBP, diastolic blood
pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SBP, systolic blood pressure; Total-C,
total cholesterol.
Numbers are percentages unless otherwise stated.
*Continuous variables are described as mean (standard deviation)
or median (first quartile–third quartile).
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(n 5 11,209); mean MPR was 68.77% (SD 15.55). These
patients showed a slightly worse cardiovascular risk profile
than that of the total sample (see Supplementary Table S8).
Statin patterns
Multiple correspondence analysis
Statin use patterns were identified from a 5-dimensional
space MCA, which accounted for 48.43% of the total
variance. (See Supplementary Table S9.)
Patterns of statin use
Three patterns of statin use were defined by MCA, on
the basis of homogeneous clinical constructs sharing the
same characteristics and representativeness (ie, sample size,
as summarized in Table 2).
Low-intensity pattern (3.82% of the population)
Individuals taking lovastatin (51.82%), pravastatin
(37.89%), or fluvastatin (10.29%), primarily, with eitherno statin change/potency decrease (42.74%) or stopped
taking statin (37.41%).
Moderate-intensity pattern (71.94% of the population)
Individuals taking simvastatin (92.08%), primarily, with
either no statin change/potency decrease (64.16%) or
stopped taking statin (29.47). The most frequently
prescribed pattern was simvastatin at moderate doses
(10–20 mg).
High-intensity pattern (24.24% of the population)
Individuals taking atorvastatin (56.51%) or simvastatin
(38.02%), primarily, with either no statin change/potency
decrease (50.94%), stopped taking statin (30.16%), or had a
statin change/potency decrease (16.93%).
Baseline characteristics were similar between statin use
patterns, except for a larger proportion of women and
diabetics in the high-intensity pattern and a smaller
proportion of hypertension in the low-intensity pattern.
Dyslipidemia was more frequent in the moderate- and high-
intensity patterns. (Table 3)
Patterns and baseline characteristics of individuals with
MPR . 70 are shown in Supplementary Tables S10–S11.
LDL-cholesterol reduction and goal attainment
Regarding LDL-C profile, mean baseline levels (mmol/
L) were somewhat lower in the low-intensity pattern total
population (3.93 [SD 1.00]), compared with moderate- and
high-intensity patterns 4.22 (SD 0.96) and 4.17 (SD 1.19),
respectively; likewise, patients with a low-intensity pattern
and MPR . 70% had lower LDL-C levels. After 1 year of
follow-up, mean LDL-C levels (mmol/L) ranged from 3.18
(SD 1.06) to 2.96 (SD 1.18) in the total population and
from 3.05 (SD 1.03) to 2.73 (SD 1.09) in the population
with MPR . 70% (Table 4).
Relative mean reductions in LDL-C at 1 year were: low
intensity, 15.70% (95% confidence interval [CI]: 222.96 to
54.36); moderate intensity, 29.72% (95% CI: 29.12–30.32);
and high intensity, 24.20% (95% CI: 28.08 to 40.32). For
patients with MPR . 70%, the 1-year LDL-C relative
reductions were greater: low intensity 23.26% (95% CI:
232.04 to 78.57); moderate intensity, 34.53% (95% CI:
33.34–35.72); and high intensity, 34.06% (95% CI:
13.62–54.51).
Figure 1 shows the probability of LDL-C goal
attainment (Fig. 1A: ,3.36 mmol/L and Fig. 1B:
,2.59 mmol/L) according to patterns of statin use and
MPR. Patients in the low-intensity pattern were less likely
to achieve the goal than were patients in the moderate-
intensity pattern. The probability of goal attainment was
higher in patients with MPR . 70% than in the total
population, except for patients in the low-intensity pattern.
However, patients in the high-intensity pattern were more
likely to achieve goal attainment than all others, regardless
of MPR (Fig. 1A and 1B). (See complete models in
Supplementary Tables S7 and S12).







5245 (24.24%) Total 5 21,636
Type of statin
Simvastatin 0 92.08 38.02 75.46
Lovastatin 51.82 0 0 1.98
Pravastatin 37.89 5.71 1.64 5.95
Fluvastatin 10.29 2.20 1.05 2.23
Atorvastatin 0 0 56.51 13.70
Rosuvastatin 0 0 2.78 0.67
Potency
Low 92.01 0 0 3.51
Moderate 7.99 99.88 22.65 77.65
High 0 0.12 74.64 18.18
Very high 0 0 2.71 0.66
1-y change
No statin/no potency 3.75 3.31 1.58 2.91
No statin/[ potency 0 0 0.04 0.01
No statin/Y potency 42.74 64.16 50.94 60.14
Statin/no potency 9.81 2.81 0.31 2.47
Statin/[ potency 5.33 0.26 0.04 0.40
Statin/Y potency 0.97 0 16.93 4.14
Stopped taking statin 37.41 29.47 30.16 29.94
Numbers are column percentages.
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The present study showed 3 clinically relevant patterns of
statin use, based on statin type, potency, and 1-year change,
observed in a high-risk cardiovascular population without
previous cardiovascular events. Correspondence analysis
enabled the identification of natural patterns of statin use
by type, potency, and changes to treatment made in a real-life
scenario. Three clinical patterns were defined according to
their capacity to achieve LDL-C reduction.26,27 Most of this
high-risk population was started on moderate simvastatin
therapy, which is in accordance with current guidelines28
and previous observational studies.12
The most frequent pattern of statin use was simvastatin
in moderate doses. The second most frequent was atorvas-
tatin or simvastatin in high or moderate potency, and the
third was lovastatin or pravastatin in low potency. The
statin type and potency characteristics of the low-intensity
pattern clearly differed from the other 2 patterns; therefore,
it is not surprising that few differences were observed
between the moderate- and high-intensity patterns. Further-
more, the criteria for prescribing one pattern or another did
not seem to be related either to baseline LDL-C levels or to
cardiovascular risk profile; goal attainment at 1 year was
also similar between all the patterns. At 1-year follow-up,
approximately half of the population remained with the
same statin but at lower potency, and one-third had stopped
taking statins, regardless of the intensity pattern. Statin
change was uncommon, and the population in the moder-
ate- and high-intensity patterns was more likely to achieve
goal attainment than those in the low-intensity pattern.We found that 16% to 26% of patients initiating statin
therapy were already at goal. This might reflect uncertainty
about patient management due to differences in cardiovas-
cular risk definition and goal attainment of the different
guidelines available at the time.6,7 Furthermore, moderate-
and high-intensity patterns showed similar baseline LDL-C
levels, and it seems that the high-intensity pattern was not
initially prescribed. Patients in both the moderate- and
high-intensity groups had baseline LDL-C levels of about
4.2 mmol/L, so that starting with moderate statin therapy
to achieve an expected reduction of approximately
1.5 mmol/L (35%) could reach treatment goals in most
cases in both groups. Nonetheless, strategies to enhance
the alignment between initial pattern prescribed and
LDL-C level or cardiovascular risk should be implemented
to improve the percentage of individuals reaching therapeu-
tic goals.
Likewise, some patients in the low-intensity group with
a baseline LDL-C level of about 4 mmol/L achieved their
goal attainment by starting with low-potency statins. How-
ever, a non-negligible proportion (31.62%) of individuals in
low-intensity patterns with higher than 4.4 mmol/L LDL-C
would likely need a higher intensity of treatment to achieve
the minimum goal (3.36 mmol/L). Furthermore, only 58%,
63%, and 66% of patients were at goal in low-, moderate-,
and high-intensity patterns, respectively, after 1 year of
treatment. These percentages of goal attainment were in
accordance with previous studies, which reported successes
ranging from 20% to 60%, depending on statin type and
regardless of cardiovascular risk.9,10,17,32,33 Thus, the pat-
terns observed in real life did not achieve the expected
Table 3 Baseline characteristics by statin use patterns
Baseline
characteristics Low Moderate High
Women 17.68 17.71 20.34
Obesity 45.40 42.04 45.34




Dyslipidemia 64.04 71.34 71.99
Hypertension 74.82 67.2 70.56
Diabetes 55.21 54.55 60.44
Age 64.83 (5.82) 63.35 (6.26) 62.90 (6.41)
CV risk* 11.52 (9.19–14.56) 11.69 (9.72–14.76) 12.00 (9.98–15.33)
BMI* 29.94 (4.65) 29.79 (4.80) 30.28 (5.04)
SBP* 144.02 (17.72) 143.71 (16.71) 144.26 (17.42)
DBP* 81.74 (11.44) 81.90 (10.50) 82.22 (10.89)
Triglycerides, mmol/L* 1.82 (1.32–2.60) 1.40 (1.03–1.97) 1.46 (1.08–2.00)
Glucose, mmol/L* 7.46 (2.94) 6.13 (2.18) 6.80 (2.58)
BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Numbers are row percentages unless otherwise stated.
*Continuous variables are described as mean (standard deviation) or median (first quartile–third quartile).
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studies as the main explanatory factor for goal attainment
failure although some authors have suggested that
genetics34,35 and lifestyle factors36 may play a role. In
our study, one-third of patients had stopped taking statins
at 1 year of treatment, which might also explain the lack
of any major differences in goal attainment observed
between patterns of statin use.
Other authors have suggested that poor adherence to
treatment might be explained by variables related to
physicians, behaviors, beliefs, unmeasured or perceived
adverse effects, age, gender, presence of comorbidities, and
costs.12,37,38,39 Importantly, patients with poor adherence
are more likely to have a higher incidence of cardiovascularTable 4 Baseline, 1-year total cholesterol and low-density lipoprote




Total-C, mmol/L* 6.10 (1.09) 6.46 (1.04) 6
Total-C , 5.17 mmol/L 18.92 9.93 1
1-y Total-C* 5.26 (1.06) 5.16 (1.09) 5
1-y Total-C , 5.17 mmol/L 48.69 54.13 5
HDL-C, mmol/L* 1.24 (0.31) 1.30 (0.36) 1
LDL-C, mmol/L* 3.93 (1.00) 4.22 (0.96) 4
LDL-C , 3.36 mmol/L 26.5 16.92 2
LDL-C , 2.59 mmol/L 7.78 3.98
1-y LDL-C* 3.18 (1.06) 3.08 (1.09) 2
1-y LDL-C , 3.36 mmol/L 57.95 63.16 6
1-y LDL-C , 2.59 mmol/L 28.12 33.46 3
HDL-C, high-density lipoprotein cholesterol; MPR, Medical Possession Ratio
Numbers are percentages unless otherwise stated.
*Continuous variables are described as mean (standard deviation).and cerebrovascular events and all-cause mortality than
adherent patients.14–16,40 In addition, recent results showed
that treatment adherence plays an important role in the
cost-effectiveness of statin treatment in primary
prevention,41 such that one of the first-line strategies to
improve statin effectiveness recommended in primary
care is to implement interventions focused on improving
adherence that take into consideration patient, GP, and
health system characteristics.42 Our results on goal attain-
ment when only adherent (MPR . 70%) patients were
considered reinforced this recommendation.
On the other hand, patients in low-intensity patterns
should be shifted to moderate patterns, as the probability of
goal attainment is higher. Likewise, high-potency statins orin cholesterol (LDL-C) levels, and percentage of goal attainment
MPR . 70%
igh Low Moderate High
.59 (1.28) 6.28 (1.05) 6.48 (1.00) 6.69 (1.25)
2.03 12.55 8.48 9.83
.12 (1.17) 5.11 (1.01) 4.94 (1.00) 4.86 (1.08)
6.42 54.34 62.91 66.76
.34 (0.36) 1.24 (0.30) 1.30 (0.35) 1.34 (0.36)
.17 (1.19) 4.12 (0.90) 4.26 (0.92) 4.27 (1.20)
3.79 18.91 14.57 21.04
7.81 2.99 3.00 7.38
.96 (1.18) 3.05 (1.03) 2.90 (1.01) 2.73 (1.09)
6.3 62.96 71.81 75.16
9.33 31.61 39.68 48.09
; Total-C, total cholesterol.
Figure 1 Probability of low-density lipoprotein cholesterol (LDL-C) goal attainment (A: LDL-C , 3.36 mmol/L and B: LDL-C ,
2.59 mmol/L) according to patterns of statin use and MPR. MPR, Medical Possession Ratio; OR, ddds ratio.
140 Journal of Clinical Lipidology, Vol 10, No 1, February 2016more intensive treatment with ezetimibe or other lipid-
lowering drugs should be recommended to patients who
require a larger LDL-C reduction to reach therapeutic
targets, patients with good treatment adherence who do not
achieve the goal with a moderate pattern of therapy or
patients at very high risk.13,17
Strengths and limitations
The access to high-quality, internally validated
electronic medical records provided a large sample size,
warranted high external validity,43 and reflected real-life
clinical conditions. Clinical trials usually include a very
definite type of individual with specific characteristics,
while at the same time excluding specific populations
such as diabetics, women, or the very elderly.44,45
In clinical trials, effectiveness is also related to very
strict control of treatment adherence and persistence.46
Observational studies also can be used for monitoring
long-term adherence.47 Whenever high persistence is taken
into account, observational studies provide results similar
to clinical trials on overall mortality and non-fatal
cardiovascular reduction.48,14 These very specific patterns
of use in clinical trials do not accurately represent
real-life clinical conditions.14–16
Low data quality could result in misclassification. In this
study, both the presence of cardiovascular risk factors and
outcomes were previously validated.20 Moreover, data on
statin exposure were obtained from the official records of
community pharmacies that invoice the National Health
Service.
To avoid selection bias, where the population with
missing data somehow differs from those with complete
data, we imputed the missing values for continuous
variables instead of excluding records with missing data.
In our study, the characteristics of the complete-case
analysis did not differ from imputed data.In addition to these strengths, we acknowledge several
study limitations. First, individuals were categorized by
patterns according to a proximity criterion using the
k-means algorithm in the correspondence analysis;
therefore, groups could differ slightly depending on the
initial seeds. Nonetheless, the patterns remained unchanged
after using multiple seeds and iterations. Second, we could
not measure some potential confounders such as physical
activity and diet and could not evaluate the reasons for the
GP’s therapeutic choices. Third, MPR was assessed on a
monthly basis, so, we could not accurately estimate
adherence. Fourth, non–HDL-C and apolipoprotein B
together with LDL-C have been shown to be adequate
target for risk reduction. However, non–HDL-C and
apolipoprotein B are not available in SIDIAP as they are
not routinely collected in laboratory tests. Fifth, the low
percentage of women is a shortcoming. However, the
proportion of women in primary prevention of the study
may be representative of our general population
considering that the percentage of women at high risk
(.10%) is very low in our context.24
Finally, the study focused only on patterns of statin use;
consequently, goal attainment in patients with combined
treatments was not analyzed.
In conclusion, 3 real-life patterns of statin use were
identified according to statin type, potency, and 1-year
change in a high-risk population from a community setting.
The prescription patterns were not related to baseline LDL
levels. Lipid management strategies in primary care should
be focused on enhancing the alignment between initial
pattern prescribed and LDL-C level or cardiovascular risk
and improving treatment adherence, including a consider-
ation of the characteristics of the patients, GPs and health
systems involved. Finally, patients started at low-potency
statins should be switched to a moderate potency because
the probability of goal attainment is higher. Likewise, more
intensive therapies and increased dose should be considered
Garcıa-Gil et al Statin use and goal attainment in a high-risk population 141in patients who require a larger LDL-C reduction to reach
therapeutic targets, patients with good treatment adherence
who do not achieve the goal with a moderate pattern of
therapy, or patients at very high risk.Acknowledgments
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